5 minute read
Sep. 28, 2022

AZD4831: an Oral Covalent Myeloperoxidase (MPO) Inhibitor for Heart Failure


oral MPO covalent inhibitor Ph. IIb/III candidate in HFpEF previous literature and selectivity opt J. Med. Chem. AstraZeneca, Gothenburg, SE

Drug Hunter Team

AZD4831 (AstraZeneca) is an oral covalent myeloperoxidase (MPO) inhibitor being developed for heart failure. Almost half of chronic heart disease patients suffer from heart failure with a preserved ejection fraction (HFpEF) and have an estimated five-year mortality rate of 75% . Improvement in vascular structure could help these [...]



Other molecules you may be interested in